血浆胰岛素样生长因子结合蛋白7因果性影响ARDS 28天死亡率:多阶段孟德尔随机化证据
结果发现血浆IGFBP7每log2升高与ARDS 28天死亡率相关(OR 1.11,95%CI 1.04-1.19),GSMR提示因果效应(OR 2.61,95%CI 1.33-5.13),且该关联由血小板计数中介(OR 1.03,95%CI 1.02-1.04)。作者结论为IGFBP7是参与ARDS 28天死亡率及血小板功能的新型因果蛋白,需进一步实验和临床研究。
要点
- GSMR联合另外四种孟德尔随机化方法提示IGFBP7对ARDS 28天死亡率有因果效应(OR 2.61,95%CI 1.33-5.13,P=.005)。
- 因果中介分析提示IGFBP7与ARDS 28天死亡率的关联由血小板计数中介(OR 1.03,95%CI 1.02-1.04,P=.01)。
- 蛋白定量 trait 汇总数据来自INTERVAL研究(n=2,504),ARDS GWAS来自iSPAAR联盟(n=534)。
- 作者结论为IGFBP7是参与ARDS 28天死亡率及血小板功能的新型因果蛋白,尚需进一步实验和临床研究。
适用人群与场景
- 孟德尔随机化分析使用INTERVAL研究(n=2,504)的蛋白定量trait汇总统计和iSPAAR联盟ARDS GWAS(n=534)。
诊断标准与关键阈值
- 原文未提及
处置流程与药物剂量
- 原文未提及
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 蛋白组学用正交偏最小二乘判别分析检测蛋白与ARDS 28天死亡率的关联,候选蛋白用GSMR分析。
- 蛋白定量trait汇总统计来自INTERVAL研究(n=2,504),ARDS GWAS来自iSPAAR联盟研究(n=534)。
- 血浆IGFBP7每log2升高与ARDS 28天死亡率相关(OR 1.11,95%CI 1.04-1.19,P=.002)。
- GSMR联合另外四种孟德尔随机化方法提示IGFBP7对ARDS 28天死亡率的因果效应(OR 2.61,95%CI 1.33-5.13,P=.005)。
- 因果中介分析提示IGFBP7与ARDS 28天死亡率的关联由血小板计数中介(OR 1.03,95%CI 1.02-1.04,P=.01)。
证据类型、等级与局限
- 证据类型:多阶段孟德尔随机化研究(含蛋白组学分析、GSMR及四种其他孟德尔随机化方法、因果中介分析)。
- 局限:原文未明确列出局限性;IgG等结论来自观察性队列蛋白组学与遗传工具变量分析,作者指出需进一步实验和临床研究。
对床旁实践的改变
- 原文未提及对急诊/ICU具体实践的改变;作者仅指出IGFBP7是参与ARDS 28天死亡率及血小板功能的新型因果蛋白,为进一步实验和临床研究的方向。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: ARDS is a devastating syndrome with heterogeneous subtypes, but few causal biomarkers have been identified.
RESEARCH QUESTION: Would multistage Mendelian randomization identify new causal protein biomarkers for ARDS 28-day mortality?
STUDY DESIGN AND METHODS: Three hundred moderate to severe ARDS patients were selected randomly from the Molecular Epidemiology of ARDS cohort for proteomics analysis. Orthogonal projections to latent structures discriminant analysis was applied to detect the association between proteins and ARDS 28-day mortality. Candidate proteins were analyzed using generalized summary data-based Mendelian randomization (GSMR). Protein quantitative trait summary statistics were retrieved from the Efficiency and safety of varying the frequency of whole blood donation (INTERVAL) study (n = 2,504), and a genome-wide association study for ARDS was conducted from the Identification of SNPs Predisposing to Altered Acute Lung Injury Risk (iSPAAR) consortium study (n = 534). Causal mediation analysis detected the role of platelet count in mediating the effect of protein on ARDS prognosis.
RESULTS: Plasma insulin-like growth factor binding protein 7 (IGFBP7) moderately increased ARDS 28-day mortality (OR, 1.11; 95% CI, 1.04-1.19; P = .002) per log2 increase. GSMR analysis coupled with four other Mendelian randomization methods revealed IGFBP7 as a causal biomarker for ARDS 28-day mortality (OR, 2.61; 95% CI, 1.33-5.13; P = .005). Causal mediation analysis indicated that the association between IGFBP7 and ARDS 28-day mortality is mediated by platelet count (OR, 1.03; 95% CI, 1.02-1.04; P = .01).
INTERPRETATION: We identified plasma IGFBP7 as a novel causal protein involved in the pathogenesis of ARDS 28-day mortality and platelet function in ARDS, a topic for further experimental and clinical investigation.
参考来源
- Dong X, Zhu Z, Wei Y, et al. Plasma Insulin-like Growth Factor Binding Protein 7 Contributes Causally to ARDS 28-Day Mortality: Evidence From Multistage Mendelian Randomization. Chest. 2020. PMID: 33189655. doi:10.1016/j.chest.2020.10.074
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。